Modality
mRNA
MOA
CDK2i
Target
DLL3
Pathway
Ferroptosis
PompeRSVCML
Development Pipeline
Preclinical
Sep 2021
→ Nov 2027
PreclinicalCurrent
NCT06986885
1,650 pts·CML
2021-09→2027-11·Recruiting
1,650 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-201.6y awayInterim· CML
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Recruit…
Catalysts
Interim
2027-11-20 · 1.6y away
CML
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06986885 | Preclinical | CML | Recruiting | 1650 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R |